Mirador Therapeutics
Jordan Zwick, CLP, currently serves as the Chief Business Officer at Mirador Therapeutics and as a Board Member at Theratechnologies Inc. Previously, Jordan held roles such as SVP of Corporate Business Development and Investor Relations at Amarin Corporation, Strategic Advisor at Prometheus Biosciences, SVP and Chief Strategy Officer at InflaRx N.V., and Head of Strategy and Business Development at Salix Pharmaceuticals. With a strong background in business development and strategy, Jordan has been instrumental in various high-profile acquisitions and financing deals throughout their career.
This person is not in any offices
Mirador Therapeutics
Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA.